Skip to content
value.today
Ginkgo Bioworks, Inc. logo

Ginkgo Bioworks, Inc.

Total raised
$52 M
1 round on record
Latest round
$52 M
Jul 2015
First round on record
Jul 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Ginkgo Bioworks, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2015$52 MNo. 1$50 to $250 million

Ginkgo Bioworks, Inc.: Raise no. 1, Jul 2015

Investors in this round

70 investors had bought by the notice of Sep 2, 2015: 70 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$52 M of $52 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bartholomew Canton · Executive Officer
  • Jason Kelly · Director, Executive Officer
  • Reshma Shetty · Director, Executive Officer
  • Peter Boynton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Reshma Shetty, President. Source: SEC Form D and 1 amendment, newest notice filed Sep 2, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Ginkgo Bioworks, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2015).

    SEC Form D · Sep 2015

  • The industry group it chose in its notices: Other.

    SEC Form D · Sep 2015

That is all the official record says: Ginkgo Bioworks, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Ginkgo Bioworks develops autonomous labs for biotechnology, enabling scientists to program biology and accelerate R&D through cloud lab services and automation products.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

No investor of Ginkgo Bioworks, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 70 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Ginkgo Bioworks, Inc.
NameRoleNamed in
Bartholomew CantonExecutive officerSep 2015
Jason KellyExecutive officerSep 2015
Reshma ShettyExecutive officerSep 2015
Jason KellyDirectorSep 2015
Peter BoyntonDirectorSep 2015
Reshma ShettyDirectorSep 2015

About

American biotechnology company.